Literature DB >> 10080829

Anticentromere autoantibodies in patients without Raynaud's disease or systemic sclerosis.

D Vázquez-Abad1, T Grodzicky, J L Senécal.   

Abstract

Anticentromere autoantibodies (ACA) are associated with Raynaud's disease and systemic sclerosis (SSc). ACA usually bind at least one of three major centromere proteins (CENPs), particularly CENP-B. We identified 16 patients with ACA who do not have Raynaud's disease or SSc. The objective of this study was to determine whether these 16 ACA differ in antigenic specificity from the ACA found in patients with Raynaud's disease or SSc. Binding of these serum ACA was tested using competition experiments with recombinant CENP-B, and native centromere proteins from HEp-2 cells and HeLa nuclear extracts in ELISAs, immunoblots, and indirect immunofluorescence assays. The ACA from these 16 patients are strikingly different from those obtained from patients who have Raynaud's disease or SSc. Only 5 of the 16 index sera (31.25%) bound CENP-B from two or more different sources by at least two methods. Six of these 16 sera (37.5%) did not bind CENP-B on ELISA, and 8 of 16 (43.75%) did not bind CENP-B on immunoblots. Three sera did not bind CENP-B either by ELISA or immunoblots. Of the 13 sera that bound CENP-B, their patterns of binding to CENP-B strongly suggested that they bind different epitopes within the CENP-B antigen. Independently of their binding to CENP-B, these sera reacted mainly with minor CENP antigens detected by HeLa nuclear extracts. We have identified unusual ACA not associated with Raynaud's disease or SSc. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10080829     DOI: 10.1006/clim.1998.4643

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  2 in total

1.  Anti-CENP-B and anti-TOPO-1-containing sera from systemic sclerosis-related diseases with Raynaud's phenomenon induce vascular endothelial cell senescence not via classical p53-p21 pathway.

Authors:  Chieh-Yu Shen; Ko-Jen Li; Pei-Hsuan Lai; Chia-Li Yu; Song-Chou Hsieh
Journal:  Clin Rheumatol       Date:  2017-09-23       Impact factor: 2.980

2.  Incidence and clinical correlation of anticentromere antibody in Thai patients.

Authors:  Krisaree Pakunpanya; Oravan Verasertniyom; Monchand Vanichapuntu; Prapaporn Pisitkun; Kitti Totemchokchyakarn; Kanokrat Nantiruj; Suchela Janwityanujit
Journal:  Clin Rheumatol       Date:  2005-10-12       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.